GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's quarterly cash and cash equivalents increased from Jun. 2013 ($47.76 Mil) to Sep. 2013 ($216.87 Mil) but then declined from Sep. 2013 ($216.87 Mil) to Dec. 2013 ($62.14 Mil).
Synageva BioPharma Corp's annual cash and cash equivalents declined from Dec. 2011 ($60.23 Mil) to Dec. 2012 ($23.88 Mil) but then increased from Dec. 2012 ($23.88 Mil) to Dec. 2013 ($62.14 Mil).
Cash and cash equivalents on banks book.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data